首页> 外文期刊>Journal of Molecular Biology >Lambda repressor n-terminal DNA-binding domain as an assay for protein transmembrane segment interactions in vivo
【24h】

Lambda repressor n-terminal DNA-binding domain as an assay for protein transmembrane segment interactions in vivo

机译:Lambda阻遏物n末端DNA结合结构域作为体内蛋白质跨膜片段相互作用的一种检测方法

获取原文
获取原文并翻译 | 示例
           

摘要

To understand the determinants of membrane protein interactions, we have developed an in vivo genetic assay system for detecting homodimerization of transmembrane (TM) segments from integral membrane proteins. Our approach is to generate gene fusions between potentially dimerizing TM segments and a cytoplasmic DNA-binding protein that lacks its intrinsic dimerization domain. This genetic approach allows us to screen and distinguish among known dimerizing domains and weakly dimerizing mutants, as well as non-dimerizing TM segments. We replaced the bacteriophage lambda cI repressor C-terminal dimerization domain with the human erythrocyte glycophorin A transmembrane segment (GpA TM). GpA TM forms SDS-resistant homodimers in vitro. Expression of this membrane-associated fusion in Escherichia coli conferred the same degree of immunity to lambda cl phages as the wild-type, intact lambda repressor. Single amino acid substitutions that disrupt the GpA TM dimer interface were introduced into the lambda-GpA TM fusion proteins. These mutations dramatically reduced immunity of E. coli to lambda cl, such that the efficiency of plating these phages increased by greater than 10,000-fold over that conferred by the wild-type lambda-GpA TM fusion. Introduction of the putatively non-dimerizing first TM from E. coli MalF into the h-TM fusion vector resulted in no immunity to lambda cl phages. Fusion of the homodimeric, periplasmically localized, mature alkaline phosphatase domain to the C terminus of the lambda-TM fusion proteins containing weakly to non-dimerizing TM segments restored immunity to lambda cI phages. Results from this in vivo genetic assay system demonstrate that (1) dimerization of the lambda cI DNA-binding domain can be promoted by dimerizing TM segments, (2) strongly, weakly, and non-dimerizing TM segments can be distinguished on the basis of their ability to confer immunity to lambda cI phages, and (3) introduction of a dimerizing periplasmic domain can provide functionality to lambda-TM fusions containing weakly to non-dimerizing TM segments. (C) 1998 Academic Press. [References: 57]
机译:为了解膜蛋白相互作用的决定因素,我们开发了一种体内遗传测定系统,用于检测膜蛋白整体中跨膜(TM)片段的同二聚化。我们的方法是在可能二聚化的TM片段与缺乏其固有二聚化结构域的细胞质DNA结合蛋白之间产生基因融合。这种遗传方法使我们能够筛选和区分已知的二聚化结构域和弱二聚化突变体以及非二聚化TM片段。我们用人红血球糖蛋白A跨膜片段(GpA TM)替换了噬菌体λcI阻遏物C末端二聚化结构域。 GpA TM在体外形成抗SDS的同型二聚体。这种膜相关融合蛋白在大肠杆菌中的表达赋予了与野生型,完整的λ阻遏物相同程度的λλ噬菌体免疫力。将破坏GpA TM二聚体界面的单个氨基酸取代引入到lambda-GpA TM融合蛋白中。这些突变显着降低了大肠杆菌对λc1的免疫力,使得这些噬菌体的铺板效率比野生型λ-GpATM融合所赋予的效率提高了10,000倍以上。从大肠杆菌MalF推定的非二聚性第一个TM导入h-TM融合载体,导致对λcl噬菌体无免疫力。同型二聚体,周质定位的成熟碱性磷酸酶结构域与包含弱至非二聚性TM段的lambda-TM融合蛋白的C末端融合,恢复了对λcI噬菌体的免疫力。该体内遗传测定系统的结果表明(1)λcI DNA结合域的二聚化可通过二聚化TM片段来促进,(2)强,弱和非二聚化TM片段可基于它们赋予λcI噬菌体免疫力的能力,以及(3)引入二聚周质结构域可以为包含弱至非二聚TM片段的lambda-TM融合体提供功能。 (C)1998年学术出版社。 [参考:57]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号